Integrating Equity in Topic Selection for Orphan Medicinal Products: Policy Implications for Health Technology Assessment in Rare Diseases
Fatemeh Hosseini, Mohammadreza Mobinizadeh, William V Padula · 2026
Read Integrating Equity in Topic Selection for Orphan Medicinal Products: Policy Implications for Health Technology Assessment in Rare Diseases by Fatemeh Hosseini, Mohammadreza Mobinizadeh, William V Padula (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13260230.txt.
Description
Fatemeh Hosseini, Mohammadreza Mobinizadeh, and William Padula published a policy paper in 2026 on how drug review agencies pick topics. Agencies that weigh health technologies must first choose which ones deserve full review. That early pick is rarely studied and often lacks fairness. Drugs for rare diseases lose out most, since their reach is small by head count.
The authors sort the problem into three parts: built-in barriers, fairness frames, and policy fixes. Barriers include habits that favor wide-impact drugs and little voice for rare-disease groups. Frames that can help weigh social value before formal review exist but are used unevenly. Fixes include open nomination for topics and special paths for rare-disease drugs. The authors call for both policy and culture change so rarity draws more care, not less.
Catalog record
| CREATOR | Fatemeh Hosseini, Mohammadreza Mobinizadeh, William V Padula |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 28 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |